SCHEMBL351801

SCHEMBL351801

O=C(NC1=CC(=O)C2OC2C1O)c1ccc(C(F)(F)F)nc1O

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PARK7 Q99497 1/20 0.47
LMNA P02545 1/20 0.38
GAA P10253 1/20 0.34
P2RX7 Q99572 2/20 0.32
NPC1 O15118 1/20 0.31
RAB9A P51151 1/20 0.31
P2RX1 P51575 1/20 0.31
P2RX3 P56373 1/20 0.31
P2RX4 Q99571 1/20 0.31
SMO Q99835 1/20 0.31
SCN10A Q9Y5Y9 1/20 0.31
PDE4A P27815 3/20 0.31
PDE4B Q07343 3/20 0.31
PDE4C Q08493 3/20 0.31
PDE4D Q08499 3/20 0.31
PDE11A Q9HCR9 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL352278 0.83 PARK7 (0.49) PARK7GAANPC1RAB9A
SCHEMBL116427 0.79 PARK7 (0.48) PARK7P2RX7NPC1RAB9AP2RX1
Dehydroxymethylepoxyquinomicin SCHEMBL1671089 0.75 PARK7 (0.54) PARK7LMNAGAAP2RX7NPC1
Dehydroxymethylepoxyquinomicin SCHEMBL14491796 0.75 PARK7 (0.54) PARK7LMNAGAAP2RX7NPC1
Dehydroxymethylepoxyquinomicin SCHEMBL14504317 0.75 PARK7 (0.54) PARK7LMNAGAAP2RX7NPC1
SCHEMBL352102 0.75 PARK7 (0.47) PARK7
SCHEMBL665471 0.74 PARK7 (0.57) PARK7LMNAGAAP2RX7NPC1
SCHEMBL352808 0.74 PARK7 (0.46) PARK7
SCHEMBL666087 0.74 PARK7 (0.64) PARK7LMNAGAANPC1RAB9A
SCHEMBL353742 0.74 PARK7 (0.54) PARK7LMNANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2411376-B1 INHIBITORS OF NF-KB PROFECTUS BIOSCIENCES INC (US) 2015-04-22 EP claimed
US-8629164-B2 Inhibitors of NF-κB PROFECTUS BIOSCIENCES, INC. (US) 2014-01-14 US claimed
US-20120015952-A1 Inhibitors of NF-KB PROFECTUS BIOSCIENCES, INC. (US) 2012-01-19 US claimed
EP-2411376-B1 INHIBITORS OF NF-KB PROFECTUS BIOSCIENCES INC (US) 2015-04-22 EP disclosed
US-8629164-B2 Inhibitors of NF-κB PROFECTUS BIOSCIENCES, INC. (US) 2014-01-14 US disclosed
US-20120015952-A1 Inhibitors of NF-KB PROFECTUS BIOSCIENCES, INC. (US) 2012-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120015952-A1 Inhibitors of NF-KB NFKBIA, IKBKB, IKBKG PARK7 3327/4885LMNA 3191/4885GAA 1468/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.